JanOne files patent for methods of using low dose naltrexone

JanOne has filed an international patent application for methods of using low dose naltrexone to treat chronic pain. JanOne is developing Jan123, a novel formulation of low dose naltrexone, to treat CRPS, an orphan disease with no current FDA-approved treatments. CRPS leaves patients in debilitating pain and suffering and, as a result, oftentimes patients resort to opioid pain medications.